Stem cell transplantation offers potentially curative therapy for patients with Myelodysplastic syndrome. A broad scale of regimens, ranging from “modified” conventional to reduced intensity to non-myeloablative regimens, has been developed and used successfully; one size does not appear to fit all. Rather, patient age, co-morbid conditions, disease stage, ferretin level, presence & severity of myelofibrosis, non-transplant chemotherapy, type of donor, source of stem cells, and other factors, all affect the decision regarding transplantation and impact on outcome. GVHD and post-SCT relapse remain problems. The optimum timing, however, and the best conditioning strategy have remained controversial, our study aimed to compare the feasibility, safety, and efficacy of both myeloablative SCT and Reduced-Intensity-Conditioning regimens in treatment of MDS.